| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD24 |
| Uniprot No | P25063-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-59aa |
| 氨基酸序列 | MGRAMVARLG LGLLLLALLL PTQIYSSETT TGTSSNSSQS TSNSGLAPNP TNATTKAAG |
| 预测分子量 | 30 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CD24重组蛋白的代表性文献(信息基于公开研究整理，部分为示例性描述)：
1. **文献名称**：*CD24 as a therapeutic target in cancer immunotherapy*
**作者**：Sagi Y. et al.
**摘要**：研究揭示了重组CD24蛋白通过结合Siglec-10受体抑制炎症反应，并在小鼠模型中证实其通过阻断“别吃我”信号增强巨噬细胞对肿瘤细胞的吞噬作用，为癌症免疫治疗提供新靶点。
2. **文献名称**：*Engineering of a high-affinity CD24-Fc fusion protein for targeted immune modulation*
**作者**：Liu X. et al.
**摘要**：报道了一种新型CD24-Fc重组融合蛋白的设计与表达，通过优化结构显著提高与Siglec-10的结合活性，实验显示其可有效抑制脓毒症模型中的过度炎症反应。
3. **文献名称**：*CD24-mediated regulation of macrophage polarization in inflammatory diseases*
**作者**：Chen L. et al.
**摘要**：利用重组CD24蛋白分析其在炎症性疾病中的作用，证明其通过调控NF-κB通路促进巨噬细胞向抗炎表型转化，为治疗类风湿性关节炎等疾病提供机制依据。
*注：以上文献信息为示例性质，实际引用需以具体论文数据库(如PubMed/Web of Science)的检索结果为准。*
CD24. also known as heat-stable antigen (HSA), is a small, heavily glycosylated cell surface protein anchored via a glycophosphatidylinositol (GPI) moiety. It plays critical roles in cell-cell interactions, immune regulation, and signal transduction. Structurally, CD24 consists of a short extracellular domain, a glycosyl-phosphatidylinositol anchor, and multiple O-linked and N-linked glycosylation sites, contributing to its functional diversity. It interacts with ligands such as Siglec-10 (sialic acid-binding immunoglobulin-type lectins) to modulate immune responses, particularly by suppressing inflammation through "don't eat me" signals that inhibit phagocytosis of healthy or apoptotic cells.
Recombinant CD24 protein is engineered using expression systems like mammalian cells (e.g., HEK293) or bacteria (E. coli) to produce soluble, glycosylated or non-glycosylated forms for research and therapeutic applications. Its production enables detailed studies of CD24's immunomodulatory functions, including its involvement in cancer progression, autoimmune diseases, and infections. For example, CD24 is overexpressed in various cancers (e.g., ovarian, breast), promoting tumor immune evasion, while its deficiency is linked to autoimmune disorders like systemic lupus erythematosus (SLE).
Recent studies highlight recombinant CD24 as a promising therapeutic agent. In COVID-19. it attenuated severe inflammation by targeting the Siglec-10 pathway to dampen cytokine storms. Preclinical models also suggest its potential in organ transplantation and sepsis. Additionally, recombinant CD24 serves as a biomarker for disease diagnosis and prognosis. Challenges remain in optimizing its stability, delivery, and specificity, but advances in protein engineering and targeted therapies continue to expand its biomedical relevance.
×
